p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy

BACKGROUND: We attempted to elucidate whether p53 expression or TP53 mutation status was associated with cancer-specific survival in adjuvant FOLFOX-treated patients with stage III or high-risk stage II colorectal cancer (CRC). METHODS: We analysed CRCs (N = 621) for the presence of TP53 alterations...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Hyeon Jeong, Bae, Jeong Mo, Wen, Xianyu, Jung, Seorin, Kim, Younghoon, Kim, Kyung Ju, Cho, Nam-Yun, Kim, Jung Ho, Han, Sae-Won, Kim, Tae-You, Kang, Gyeong Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474280/
https://www.ncbi.nlm.nih.gov/pubmed/30894685
http://dx.doi.org/10.1038/s41416-019-0429-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6474280/
https://www.ncbi.nlm.nih.gov/pubmed/30894685
http://dx.doi.org/10.1038/s41416-019-0429-2

Ejemplares similares